Skip to main content

Francesc Xavier Serra Marin

Institutions of which they are part

Research assistant
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Francesc Xavier Serra Marin

Institutions of which they are part

Research assistant
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

ScreenEC, validació d'una eina de triatge no invasiu en càncer d'endometri

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Josep Castellví Vives, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Lourdes Elena Salazar Huayna
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 99946
Reference: SLT036/24/000059
Duration: 21/12/2024 - 31/12/2026

Telemedicine-guided Patients Reported Outcome Measures (PROMs): side efects screening and early intervention to impact in quality of life of gynaecological cancer patients.

IP: Vicente Bebia Conesa
Collaborators: Maria Asuncion Perez Benavente, Francesc Xavier Serra Marin, Antonio Gil Moreno, Martina Angeles Fite, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Melissa Bradbury Lobato, Melek Denizli
Funding agency: Fundació La Marató de TV3
Funding: 96737.5
Reference: 202403-30
Duration: 28/02/2025 - 27/02/2028

Telemedicine-guided Patients Reported Outcome Measures (PROMs): side efects screening and early intervention to impact in quality of life of gynaecological cancer patients.

IP: Vicente Bebia Conesa
Collaborators: Maria Asuncion Perez Benavente, Francesc Xavier Serra Marin, Antonio Gil Moreno, Martina Angeles Fite, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Melissa Bradbury Lobato, Melek Denizli , Telemedicine-guided Patients Reported Outcome Measures (PROMs): side efects screening and early intervention to impact in qualit
Funding agency: Fundació La Marató de TV3
Funding: 96737.5
Reference: 202403-30
Duration: 28/02/2025 - 27/02/2028

Related news

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

Related professionals

Carmen Tur Gomez

Carmen Tur Gomez

Main researcher
Clinical Neuroimmunology
Read more
José Morote Garcia

José Morote Garcia

Research technician
Infection and immunity in pediatric patients
Read more
Yoursa El-Kasmy El Kasmi

Yoursa El-Kasmy El Kasmi

Administration and Management
General Surgery
Read more
Júlia Cera Puig

Júlia Cera Puig

Research technician
Clinical Pharmacology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.